Compare Ascendis Pharma A/S (ASND) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Orion Office REIT Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Orion Office REIT Inc trades at $2.75 (market cap $156.28M). The key difference: Ascendis Pharma A/S is far larger — about 113.5× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 2.91% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | ONL | |
|---|---|---|
Market Cap | $17.74B | $156.28M |
Sector | Health | Real Estate |
52-Week High | $277.18 | $3.04 |
52-Week Low | $163.32 | $1.93 |
Enterprise Value | $18.11B | $639.94M |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ONL trades at $2.75, down 1.08% on the day, with a neutral technical signal and bearish moving averages. The company reported a net loss of $139.31 million in 2025, with revenue declining to $147.65 million. Despite negative profitability, the stock trades at a low price-to-book ratio of 0.26 and recently announced a $0.02 dividend. Strategic reviews and portfolio repositioning are ongoing, as noted in recent earnings calls (Business Wire, 2026-05-07).
Outlook remains challenged by persistent losses and high debt, but strategic asset sales and refinancing improvements offer potential stabilization. Risks include further revenue declines and office sector headwinds, while analyst sentiment is evenly split between buy and hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
